Market Spotlight: Osteoarthritis and Osteoarthritis Pain
Market Spotlight: Osteoarthritis and Osteoarthritis Pain
$1,318.00
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising disease background, treatment overview, key pipeline drugs, clinical trials, and a 10-year global disease prevalence forecast.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain drugs market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 308.9 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 358.4 million prevalent cases by 2026.
- The global prevalence of osteoarthritis is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
- The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II. Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
- High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II, Phase IIb, and Phase III trial results, an expected PDUFA date for an sNDA, and an expected decentralized approval in the EU.
- The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 11.3%, and the average probability a drug advances from Phase III is 50%. Drugs, on average, take 11.3 years from Phase I to approval in the osteoarthritis and osteoarthritis market, as well as in the overall rheumatology (non autoimmune) space.
- There have been 45 licensing and asset acquisition deals involving osteoarthritis drugs during 2014–19. The $2,610m collaboration agreement signed in 2016 between Regeneron and Teva Pharmaceuticals to develop and commercialize fasinumab was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 57% of trials in Phase I–II, and 43% in Phase III–IV.
- The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the osteoarthritis treatment market is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 112 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Non-pharmacological treatment
9 Pharmacological treatment
10 Surgery
11 EPIDEMIOLOGY
14 MARKETED DRUGS
18 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
27 Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
28 Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
29 Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
31 Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
32 Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
35 KEY UPCOMING EVENTS
36 KEY REGULATORY EVENTS
36 Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions
36 FDA Misses Zilretta Goal Date, Flexion Says
36 Global Device Approvals Snapshot: 4–10 June 2019
36 Invossa Approval Revoked As Korea Confirms False Data Submission
37 Invossa Gene Therapy Controversy Grows As Government, Patients Take Action
37 Korea Suspends First Approved Gene Therapy Pending Component Discrepancy Probe
37 Global Device Approvals Snapshot For March 26–April 1, 2019
39 PROBABILITY OF SUCCESS
40 LICENSING AND ASSET ACQUISITION DEALS
40 $5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day
41 PARENT PATENTS
42 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
48 BIBLIOGRAPHY
48 Prescription information
50 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of osteoarthritis (knee or hip), 2019–28
18 Figure 2: Overview of pipeline drugs for osteoarthritis in the US
18 Figure 3: Pipeline drugs for osteoarthritis, by company
19 Figure 4: Pipeline drugs for osteoarthritis, by drug type
19 Figure 5: Pipeline drugs for osteoarthritis, by classification
29 Figure 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019): Phase III – OA Safety Study (vs. NSAIDs)
31 Figure 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019): Phase III – OA of Hip or Knee (6 Months EU Study)
32 Figure 8: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018): Phase IIb – PARA_005 (Knee Pain from Osteoarthritis and BMELs)
34 Figure 9: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018): Phase IIb – SM04690-OA-04
35 Figure 10: Key upcoming events in osteoarthritis
39 Figure 11: Probability of success in the osteoarthritis pipeline
40 Figure 12: Licensing and asset acquisition deals in osteoarthritis, 2015–20
41 Figure 13: Parent patents in osteoarthritis
43 Figure 14: Clinical trials in osteoarthritis
43 Figure 15: Top 10 drugs for clinical trials in osteoarthritis
44 Figure 16: Top 10 companies for clinical trials in osteoarthritis
44 Figure 17: Trial locations in osteoarthritis
45 Figure 18: Osteoarthritis trials status
46 Figure 19: Osteoarthritis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of osteoarthritis (knee or hip), 2019–28
15 Table 2: Marketed drugs for osteoarthritis
20 Table 3: Pipeline drugs for osteoarthritis in the US
26 Table 4: GLPG1972 for Osteoarthritis and Osteoarthritis Pain (July 14, 2019)
27 Table 5: Multiple Drugs for Osteoarthritis and Osteoarthritis Pain (June 25, 2019)
28 Table 6: Tanezumab for Osteoarthritis and Osteoarthritis Pain (April 18, 2019)
30 Table 7: Tanezumab for Osteoarthritis and Osteoarthritis Pain (January 29, 2019)
31 Table 8: Zilosul for Osteoarthritis and Osteoarthritis Pain (December 18, 2018)
33 Table 9: Lorecivivint for Osteoarthritis and Osteoarthritis Pain (October 23, 2018)
42 Table 10: Historical global sales, by drug ($m), 2014–18
42 Table 11: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Neuroendocrine tumors (NET) 
Sign up to the